Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine

Clinical and Translational Oncology

Volumn 11, Issue 1, 2009, Pages 35-40

  Gasent Blesa, Joan Manel ^a   Alberola Candel, Vicente ^b   Provencio Pulla, Mariano ^c   Esteban González, Emilio ^d   Martín Algarra, Salvador ^e  

^a Hospital de Denia Marina Salud   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Ovarian cancer; Pemetrexed Gemcitabine; Platinum resistant

Indexed keywords

ANTIEMETIC AGENT; CA 125 ANTIGEN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PEMETREXED; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; METHODOLOGY; MIDDLE AGED; MORTALITY; OVARY TUMOR; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65349128946     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0308-z     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinumbased chemotherapy for ovarian cancer: Implications for patient management and clinical trial design. J Clin Oncol 22:3120
3. Slayton RE, Creasman WT, Petty W et al (1979) Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: A Gynecologic Oncology Group Study. Cancer Treat Rep 63:2089
4. Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 16:405
5. Muggia FM, Hainsworth JD, Jeffers S et al (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987
6. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312
7. Clarke-Pearson DL, Van Le L, Iveson T et al (2001) Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 19:3967
8. Hochster H, Wadler S, Runowicz C et al (1999) Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 17:2553
9. Friedlander M, Millward MJ, Bell D et al (1998) A phase II study of gemcitabine in platinum pretreated patients with advanced epithelial ovarian cancer. Ann Oncol 9:1343
10. Lund B, Hansen OP, Theilade K et al (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530
11. Sorensen P, Hoyer M, Jakobsen A et al (2001) Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81:58
12. Rothenberg ML, Liu PY, Nahhas WA et al (1999) A phase II trial of vinorelbine in relapsed and refractory ovarian cancer. A Southwest Oncology Group study (SWOG-9324) (abstract). Proc Am Soc Clin Oncol 18:383a
13. Markman M, Kennedy A, Sutton G et al (1998) Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70:272
14. Baur M, Fazeny-Doerner B, Hudec M et al (2006) Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients - long-term results of a phase II study. Cancer Invest 24:22
15. Look KY, Muss HB, Blessing JA, Morris M (1995) A phase II trial of 5-fluorouracil and highdose leucovorin in recurrent epithelial ovarian car cinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 18:19
16. Williams CJ (2001) Tamoxifen for relapse of ovarian cancer (Cochrane Review). Cochrane Database Syst Rev 1:CD001034
17. Markman M, Iseminger KA, Hatch KD et al (1996) Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62:4
18. Smyth JF, Gourley C, Walker G et al (2007) Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13:3617
19. Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165
20. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180
21. Chura JC, Van Iseghem K, Downs LS Jr et al (2007) Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107:326
22. Wright JD, Hagemann A, Rader JS et al (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107:83
23. Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105:3
24. Lordick F, Geinitz H, Theisen J et al (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. Int J Radiat Oncol Biol Phys 64:1295
25. Shih C, Chen VJ, Gossett LS, et al (1997) LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 57:1116-1123
26. Zhao R, Babani S, Gao F et al (2000) The mechanism of transport of the multitargeted antifolate MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexed. Clin Cancer Res 6:3687-3695
27. Shepherd FA, Dancey J, Arnold A et al (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92: 595-600
28. Dean-Colomb W, Esteva FJ (2008) Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 35[2 Suppl 2]:S31-S38; quiz S40
29. Galsky MD, Mironov S, Iasonos A et al (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25:265-270
30. Paz-Ares L, Ciruelos E, García-Carbonero R et al (2002) Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol 29[6 Suppl 18]:69-75
31. Smith I (2004) Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Oncology (Williston Park) 18[13 Suppl 8]:63-65
32. Ceresoli GL, Castagneto B, Zucali PA et al (2008) Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99:51-56
33. Teicher BA, Alvarez E, Liu P et al (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 mu rine mammary carcinoma. Semin Oncol 26[Suppl 6]:55-62
34. Tonkinson J, Worzalla JF, Teng ChH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676
35. Nagai S, Takenaka K, Sonobe M et al (2008) Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 54:166-175
36. Adjei AA, Erichman C, Sloan JA et al (2000) Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with solid tumors. J Clin Oncol 18:1748-1757
37. Mey V, Giovannetti E, De Braud F et al (2006) In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95:289-297
38. Giovannetti E, Mey V, Danesi R et al (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936-2943
39. Smith I (2004) Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Oncology (Williston Park) 18:63-65
40. Kalykaki A, Vamvakas L, Agelaki S et al (2006) A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. Oncology 71:197-203
41. Hensley ML, Derosa F, Gers SR et al (2006) A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): Dosing results and evidence of activity. J Clin Oncol 24[Suppl]:5083
42. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
43. Rustin GJ, Bast RC Jr, Kelloff GJ et al (2004) Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10:3919-3926
44. Fung-Kee-Fung M, Oliver T, Elit L et al (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14:195-208